Insights on Conjugate Pneumococcal Vaccines

Author(s):

Christina M. Madison, PharmD, FCCP, AAHIVP,Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP

The vaccination experts analyze the impact of currently approved pneumococcal vaccines on otitis media prevention and compare the newer conjugate vaccines (PCV15 and PCV20) to their predecessors in terms of strain coverage and clinical efficacy.

EP: 1.Symptomatology and Transmission of Pneumococcal Infection

EP: 2.Manifestation of Pneumococcal Disease in Adults

EP: 3.High-Risk Populations for Severe Pneumococcal Infection

EP: 4.Patient Burden Associated with Pneumococcal Disease

EP: 5.Vaccination Efforts to Mitigate Pneumococcal Outbreaks

EP: 6.Comparing and Contrasting the Characteristics of the FDA-Approved Pneumococcal Vaccines

EP: 7.Target Patient Populations for Pneumococcal Vaccines

EP: 8.ACIP Recommendations for Pneumococcal Vaccination

EP: 9.Clinical Considerations for Pneumococcal Vaccination Scheduling

EP: 10.Clinical Data Supporting Pneumococcal Vaccination

Now Viewing

EP: 11.Insights on Conjugate Pneumococcal Vaccines

EP: 12.Future Considerations for Pneumococcal Vaccination

EP: 13.Barriers to Administering Pneumococcal Vaccines and Best Practices for Overcoming Them

EP: 14.Optimizing Pneumococcal Vaccination Efforts in High-Risk Patients

EP: 15.Closing Thoughts From The Panel On Pneumococcal Vaccination

What effect do currently approved pneumococcal vaccines have on preventing otitis media?
How do the newer conjugate vaccines (PCV15 and PCV20) compare to their predecessors in terms of strain coverage and clinical efficacy?
What are your considerations for selecting between conjugate vaccines for adult patients who are vaccine-naïve?
When would you use PCV20 instead of PCV15 and vice versa?